An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Trial Profile

An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2018

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2018 Results of first part (n=302) in which patients with schizophrenia were switched from standard-of-care (SOC) antipsychotic therapy to 6 weeks treatment with lumateperone and then switched back to SOC, presented at the 171st Annual Meeting of the American Psychiatric Association.
    • 04 May 2018 According to an Intra-Cellular Therapies media release, results from this study will be presented at the 2018 American Psychiatric Association (APA) Annual Meeting.
    • 07 Dec 2017 According to an Intra-Cellular Therapies media release, results from this trial were presented at the 56th Annual Meeting of the American College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top